PEG-ADA enzyme replacement and gene therapy sequencing for ADA-SCID c.986C>T (p.Ala329Val)

ADA c.986C>T (p.Ala329Val) is a pathogenic missense variant in the ADA barrel domain that severely impairs enzymatic activity, leading to toxic deoxyadenosine accumulation and profound T/B/NK lymphocyte dysfunction. For this variant, pegademase bovine (Revcovi/PEG-ADA) enzyme replacement therapy is the immediate bridging strategy, but hematopoietic stem cell gene therapy (HSC-GT) with lentiviral ADA cDNA transfer represents the definitive curative option with superior long-term immune reconstitution compared to matched unrelated donor HSCT. The sequencing decision—ERT bridge followed by HSC-GT versus early HSCT—should be driven by donor availability, patient age at diagnosis, and center expertise.

Aiuti et al. (NEJM 2009, PMID:19713094) established the proof of concept for retroviral ADA-HSC-GT with durable immune reconstitution in 10 patients over 4 years. The subsequent lentiviral vector program (OTL-101, Orchard Therapeutics) showed CD4+ T-cell counts >500/μL in 90% of patients at 24 months in the Phase 2 trial (Shaw et al., NEJM 2017, PMID:28910237). PEG-ADA (Revcovi) provides metabolic detoxification within days—plasma dAXP clearance is typically >80% within 2 weeks—allowing immune reconstitution sufficient for opportunistic infection prevention during the transplant preparatory phase. Structural analysis of ADA p.Ala329Val predicts destabilization of the C-terminal barrel with reduced Zn2+ coordination geometry, consistent with the near-zero residual enzymatic activity (<1% of normal) reported in fibroblast assays for this allele.

PEG-ADA ERT does not achieve full immune reconstitution—T-cell counts plateau at subtherapeutic levels in most patients over time, and long-term ERT is associated with progressive loss of efficacy due to anti-PEG antibody development. For HSC-GT, conditioning intensity (busulfan AUC targeting) must be calibrated carefully in this immunocompromised population to avoid regimen-related toxicity while ensuring sufficient engraftment. Long-term genotoxicity data from lentiviral integration sites remain under surveillance; no insertional oncogenesis events have been reported in ADA-GT through 15+ year follow-up, but the dataset is limited. ERT must be discontinued before HSC-GT to avoid PEG-ADA competing with gene-corrected cells for proliferative advantage—the washout timing requires careful coordination.